1. HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma
- Author
-
Genji Kawade, Sachiko Ishibashi, Kouhei Yamamoto, Yuji Sekine, Morito Kurata, Masumi Ikeda, Iichiroh Onishi, Masanobu Kitagawa, Masahide Yamamoto, Ayaka Honda, Yuko Kinowaki, Serina Nomura, Sho Fukuda, and Shiori Watabe
- Subjects
Programmed cell death ,Gene knockdown ,Fatty acid metabolism ,Cell growth ,business.industry ,Fatty Acids ,Fatty acid beta-oxidation ,medicine.disease ,Prognosis ,Pathology and Forensic Medicine ,Lymphoma ,chemistry.chemical_compound ,chemistry ,hemic and lymphatic diseases ,Mitochondrial Trifunctional Protein, beta Subunit ,Cancer research ,medicine ,Immunohistochemistry ,Animals ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Prospective Studies ,business ,HADHB - Abstract
In haematological malignancies, such as malignant lymphoma, reprogramming of fatty acid metabolism favours tumour cell survival and drug resistance. Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha (HADHA), an enzyme involved in fatty acid beta-oxidation (FAO), is overexpressed in high-grade lymphoma and is a predictor of poor prognosis in diffuse large B-cell lymphoma (DLBCL). HADHB forms a heterodimer with HADHA and functions as an FAO enzyme together with HADHA; however, the relevance of its expression in malignant lymphoma is unknown. In this study, we investigated the roles and antitumour effects of HADHB expression in malignant lymphoma. Immunohistochemical analysis showed that HADHB was frequently overexpressed in the high-grade lymphoma subtype. HADHB overexpression was observed in 68% (87/128) of DLBCL cases and was an independent predictor of poor prognosis (p=0.001). In vitro analysis demonstrated that HADHB knockdown suppressed cell proliferation in LCL-K and MD901 cells (p
- Published
- 2020